Andromeda Surgical vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Surgical robotics company achieving world's first robotic-assisted HoLEP for prostate treatment; YC-backed targeting $10B+ urology market with Richard Wolf and Quanta System partnerships.
About
Andromeda Surgical is a surgical robotics company developing autonomous robots for urological procedures — specifically targeting the HoLEP (Holmium Laser Enucleation of the Prostate) procedure used to treat benign prostatic hyperplasia (BPH, enlarged prostate), a condition affecting 50%+ of men over 50. Founded in 2023 by CEO Nick Damiano and CTO Kartik Tiwari and a Y Combinator S23 graduate, Andromeda raised $500,000 in seed funding from CoreNest and YC, and achieved the world's first robotic-assisted HoLEP procedure in December 2024 — a significant clinical milestone.\n\nAndromeda's surgical robot assists urologists performing HoLEP procedures by providing precise laser energy delivery and tissue manipulation, targeting the improvement in procedural consistency and outcome reproducibility that robotic assistance provides across varying surgeon skill levels. HoLEP is considered the gold standard treatment for BPH but has a steep learning curve — it requires 30-50+ procedures to achieve proficiency, limiting its adoption to high-volume academic medical centers. Andromeda's robotic assistance aims to make HoLEP accessible at community hospitals by reducing the expertise barrier.\n\nIn 2025, Andromeda competes in the surgical robotics market with Intuitive Surgical (da Vinci for soft tissue surgery), GYRUS Medical (urological instruments), and emerging robotic surgery startups targeting different procedural niches for surgical automation. The global urology surgery robotics market represents a $3+ billion opportunity, with the broader HoLEP addressable market estimated at $10+ billion. Strategic partnerships with Richard Wolf (endoscopy equipment) and Quanta System (laser platforms) provide Andromeda with established distribution channels and clinical credibility. The 2025 strategy focuses on additional clinical procedures to build the safety evidence required for FDA clearance, expanding from the first-in-human milestone toward a pivotal trial for regulatory submission.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Andromeda Surgical vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.